A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability and Efficacy of Caveolin-1-ScaffoldingProtein-Derived Peptide (LTI-03) in Patients with Idiopathic Pulmonary Fibrosis (RENEW)

Principal Investigator

Dr Peter Saunders

Contact us

Email: emcrf@ouh.nhs.uk

IRAS number

1011923